跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 213 条关于
“APOB”
全部
213
临床试验
106
药物
64
机构
2
资讯
41
去年
Muvalaplin Shows Promise in Lowering Lipoprotein(a) Levels in Phase II Trial
2个月前
Longevity Biomarkers Move From Wellness Trend to Precision Medicine: Experts Chart the Future of Proactive Health
去年
Wave Life Sciences Advances Obesity and Cardiometabolic Programs with RNA Therapies
去年
Plozasiran Shows Promise in Reducing Triglycerides in Phase 3 and Extension Studies
去年
Lilly's Muvalaplin Significantly Reduces Lipoprotein(a) Levels in Phase 2 Trial
2年前
Orforglipron Shows Promise in Reducing Cardiovascular and Inflammatory Markers in Phase II Trial
去年
Oral Muvalaplin Shows Promise in Lowering Lipoprotein(a) Levels in Phase 2 Trial
2年前
Obicetrapib Shows Significant LDL-C Reduction in Phase 3 Trial for Heterozygous Familial Hypercholesterolemia
去年
Merck's Enlicitide Shows Promise as First Oral PCSK9 Inhibitor in Phase 3 Trials
去年
Plozasiran Shows Promise in Reducing Triglycerides in Familial Chylomicronemia Syndrome and Severe Hypertriglyceridemia
第 1 页,共 5 页
上一页
下一页